U.S. Food and Drug Administration Expands Approval of Sprycel® (dasatinib) to Include Treatment of Children with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

November 10, 2017
PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #BristolMyers--U.S. Food and Drug Administration Expands Approval of Sprycel® (dasatinib) to Include Treatment of Children

Advertisement

Recent related news

Allergan Plc (NYSE:AGN) has landed an approval from the US Food and Drugs Administration (FDA) for the use of its VRAYLAR drug for the treatment of...
5 days ago • Proactive Investors
TRENTON, N.J. (AP) — U.S. regulators have approved the first new treatment in nearly two decades to prevent internal bleeding in certain patients with...
2 days ago • SeattlePI.com
An easier-to-take vaccine from an East Bay company, which could shift the fight against the surging, deadly hepatitis B virus, won regulatory approval Thursday....
1 week ago • bizjournals
When you are trying to get pregnant (TTC), it is important to understand that not all lubricants are created equal, and you need to be discerning when selecting...
2 days ago • PRWeb
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today a successful Type A...
1 week ago • Business Wire
(Reuters) - Dynavax Technologies Corp's hepatitis B vaccine won the U.S. Food and Drug Administration's approval on the third attempt and Chief Executive Eddie...
1 week ago • Reuters

You might like